We are live on ! Find out more
EVOK

Evoke Pharma
EVOK

Delisted

EVOK was delisted on the 16th of December, 2025.

Back to rankings

19 hedge funds and large institutions have $7.91M invested in Evoke Pharma in 2018 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 2

0.83% less ownership

Funds ownership: 19.14% → 18.3% (-0.83%)

10% less funds holding

Funds holding: 21 → 19 (-2)

18% less capital invested

Capital invested by funds: $9.64M → $7.91M (-$1.73M)

40% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 5

Holders
19
Holders Change
-2
Holders Change %
-9.52%
% of All Funds
0.42%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
3
Reduced
2
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SIM
Spark Investment Management
New York
+$49.2K
2
BFM
Boothbay Fund Management
New York
+$30K
3
BlackRock
BlackRock
New York
+$11.1K
4
Vanguard Group
Vanguard Group
Pennsylvania
+$8.88K

Top Sellers

Rank Fund Capital Flow
1
JP Morgan Chase
JP Morgan Chase
New York
-$111K
2
PNC Financial Services Group
PNC Financial Services Group
Pennsylvania
-$82K
3
VF
Virtu Financial
New York
-$80K
4
TSS
Two Sigma Securities
New York
-$55K
5
UBS Group
UBS Group
Switzerland
-$9.62K

EVOK Hedge Fund Activity: Q4 2018 in Review

19 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in Evoke Pharma (EVOK) for Q4 2018, worth a combined $7.91M — down 18% from $9.64M a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of EVOK and 3 opened new positions — a net loss of 2 holders — while 2 trimmed existing stakes and 3 added.

The largest buyer was Spark Investment Management, opening a new position worth an estimated $49.2K. The largest seller was JP Morgan Chase, exiting entirely with an estimated $111K sold.

  • 19 institutional investors held Evoke Pharma (EVOK) as of Q4 2018, down from 21 in Q3 2018.
  • Funds reported $7.91M of Evoke Pharma stock for Q4 2018, down 18% quarter-over-quarter.
  • 3 funds opened new Evoke Pharma positions in Q4 2018 and 5 closed out, a net change of -2 holders.
  • The largest Evoke Pharma buyer in Q4 2018 was Spark Investment Management, an estimated $49.2K added.
  • The largest Evoke Pharma seller in Q4 2018 was JP Morgan Chase, an estimated $111K sold.

Based on aggregated 13F filings for Q4 2018.